MedPath

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

Conditions
Type 1 Diabetes Mellitus
First Posted Date
2010-01-14
Last Posted Date
2014-06-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT01049633
Locations
🇺🇸

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status

First Posted Date
2009-12-25
Last Posted Date
2016-12-16
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
34
Registration Number
NCT01040091
Locations
🇺🇸

University of Colorado CTRC CRS, Aurora, Colorado, United States

Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age

Phase 2
Withdrawn
Conditions
Influenza
Interventions
First Posted Date
2009-12-23
Last Posted Date
2014-08-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT01037634

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

Phase 2
Terminated
Conditions
Tick-Borne Encephalitis
Encephalitis, Tick-Borne
Tick-Borne Disease
Glycoprotein E, Flavivirus
NSI Protein, Flavivirus
Interventions
Biological: FSME-IMMUN 0.5ml Baxter
First Posted Date
2009-12-14
Last Posted Date
2018-07-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
69
Registration Number
NCT01031537
Locations
🇺🇸

Rocky Mountain Laboratory (RML), Hamilton, Montana, United States

🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Completed
Conditions
Papilloma Viral Infection
First Posted Date
2009-12-11
Last Posted Date
2018-10-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1321
Registration Number
NCT01030562
Locations
🇺🇸

Cincinnati Children?s Hospital Medical Center - Adolescent Medicine, Cincinnati, Ohio, United States

🇺🇸

Kaiser Permanente Crescent Medical Center - Pediatrics/Adolescent Medicine, Tucker, Georgia, United States

🇺🇸

University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

and more 4 locations

EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults

Phase 1
Completed
Conditions
Plasmodium Falciparum Malaria
Interventions
Drug: Placebo
Biological: EBA-175 RII-NG Malaria Vaccine
First Posted Date
2009-12-04
Last Posted Date
2013-03-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
60
Registration Number
NCT01026246
Locations
🇬🇭

Noguchi Memorial Institute for Medical Research - Immunology, Legon, Greater Accra, Ghana

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

Phase 1
Completed
Conditions
Paramyxoviridae Infections
Virus Diseases
Interventions
Drug: rHPIV3cp45
Drug: rHPIV3cp45 placebo
First Posted Date
2009-11-30
Last Posted Date
2013-01-03
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
12
Registration Number
NCT01021397
Locations
🇺🇸

Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso

Phase 1
Completed
Conditions
Malaria
Interventions
Biological: Ad35.CS.01 Circumsporozoite Malaria Vaccine
Drug: Placebo
First Posted Date
2009-11-23
Last Posted Date
2014-06-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
48
Registration Number
NCT01018459
Locations
🇧🇫

Centre National de Recherche et de Formation sur le Paludisme - Research and Training, West Africa, Burkina Faso

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

Recruiting
Conditions
EBV
HSV
VZV
CMV
HPV
First Posted Date
2009-11-11
Last Posted Date
2025-06-05
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
600
Registration Number
NCT01011712
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Alloantibodies in Pediatric Heart Transplantation

Terminated
Conditions
Pediatric Heart Transplantation
Pediatric Heart Transplant Recipients
Interventions
Drug: Induction Therapy
Procedure: Intraoperative plasma exchange/pheresis
Procedure: Short-term post-operative plasmapheresis
Drug: Immunoglobulins, Intravenous
First Posted Date
2009-10-30
Last Posted Date
2017-04-20
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
290
Registration Number
NCT01005316
Locations
🇺🇸

Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

🇺🇸

Children's Hospital at Montefiore, Bronx, New York, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath